Trials / Recruiting
RecruitingNCT05524935
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
A Phase II Trial of Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective phase II multi-center trial of the combination of the PARP inhibitor olaparib with the immune checkpoint inhibitor pembrolizumab in advanced uveal melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | Pembrolizumab Day 1 of each 21 day (3 week) cycle |
| DRUG | Olaparib | Olaparib by mouth days 1-21 of each 21 day (3 week) cycle |
Timeline
- Start date
- 2022-10-11
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2022-09-01
- Last updated
- 2026-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05524935. Inclusion in this directory is not an endorsement.